Article

4 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 74, n° 6
pages 1220-1233 (juin 2016)
Doi : 10.1016/j.jaad.2015.11.033
accepted : 12 November 2015
Reviews

Keratoacanthoma (KA): An update and review
 

Bartlomiej Kwiek, MD, PhD a, , Robert A. Schwartz, MD, MPH b
a Dermatology and Immunodermatology, Medical University of Warsaw, Warsaw, Poland 
b Dermatology and Pathology, Rutgers University New Jersey Medical School, and Rutgers University School of Public Affairs and Administration, Newark, New Jersey 

Reprint requests: Bartlomiej Kwiek, MD, PhD, Dermatology and Immunodermatology, Medical University of Warsaw, Koszykowa 82A Street, 02-008 Warsaw, Poland.Dermatology and ImmunodermatologyMedical University of WarsawKoszykowa 82A StreetWarsaw02-008Poland
Abstract

Keratoacanthoma (KA) is a common but underreported tumor of the skin. Two striking features of KA are its clinical behavior with spontaneous regression after rapid growth and its nosological position on the border between benignity and malignancy. We review current knowledge on the clinical, histopathological, and dermoscopic features of KA to ensure a proper diagnosis and describe its variants, including different types of multiple KAs. We highlight current concepts of KA ethiopathogenesis with special emphasis on the genetic background of multiple familial KA, the role of Wnt signaling pathway, and induction of KA by BRAF inhibitors and procedures of esthetic dermatology. Finally, treatment strategies are presented with surgical excision as a first option, followed by other modalities, including intralesional chemotherapy, topical and systemic agents, lasers, cryotherapy, and photodynamic therapy.

The full text of this article is available in PDF format.

Key words : BRAF inhibitor, erlotinib, Ferguson-Smith, Grzybowski, histopathology, keratoacanthoma, multiple keratoacanthoma, multiple self-healing squamous epithelioma, squamous cell carcinoma, treatment

Abbreviations used : GEKA, KA, MSHSE, MTS, SCC



 Funding sources: None.
 Conflicts of interest: None declared.



© 2015  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline